Amplification of FRS2 and Activation of FGFR/FRS2 Signaling Pathway in High-Grade Liposarcoma
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Fibroblast growth factor (FGF) receptor (FGFR) substrate 2 (FRS2) is an adaptor protein that plays a critical role in FGFR signaling. FRS2 is located on chromosome 12q13-15 that is frequently amplified in liposarcomas. The significance of FRS2 and FGFR signaling in high-grade liposarcomas is unknown. Herein, we first comparatively examined the amplification and expression of FRS2 with CDK4 and MDM2 in dedifferentiated liposarcoma (DDLS) and undifferentiated high-grade pleomorphic sarcoma (UHGPS). Amplification and expression of the three genes were identified in 90% to 100% (9–11 of 11) of DDLS, whereas that of FRS2, CDK4, and MDM2 were observed in 55% (41 of 75), 48% (36 of 75), and 44% (33/75) of clinically diagnosed UHGPS, suggesting that these “UHGPS” may represent DDLS despite lacking histologic evidence of lipoblasts. Immunohistochemical analysis of phosphorylated FRS2 protein indicated that the FGFR/FRS2 signaling axis was generally activated in about 75% of FRS2-positive high-grade liposarcomas. Moreover, we found that FRS2 and FGFRs proteins are highly expressed and functional in three high-grade liposarcoma cell lines: FU-DDLS-1, LiSa-2, and SW872. Importantly, the FGFR selective inhibitor NVP-BGJ-398 significantly inhibited the growth of FU-DDLS-1 and LiSa-2 cells with a concomitant suppression of FGFR signal transduction. Attenuation of FRS2 protein in FU-DDLS-1 and LiSa-2 cell lines decreased the phosphorylated extracellular signal–regulated kinase 1/2 and AKT and repressed cell proliferation. These findings indicate that analysis of FRS2 in combination with CDK4 and MDM2 will more accurately characterize pathologic features of high-grade liposarcomas. Activated FGFR/FRS2 signaling may play a functional role in the development of high-grade liposarcomas, therefore, serve as a potential therapeutic target. Cancer Res; 73(4); 1298–307. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 1×
“Deregulation of FGFR signaling is associated with many developmental syndromes (3).”
Gene expression profiling of human sarcomas: insights into sarcoma biology.
Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., Glatfelter, A. A., Duray, P. H., & Meltzer, P. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1699 · Cited by 353 · cited 1×
“Liposarcomas with similar morphologic appearance can follow different clinical courses and show divergent responses to systemic therapy (12, 13).”
Functional Copy-Number Alterations in Cancer
Taylor, B. S., Barretina, J., Socci, N. D., DeCarolis, P., Ladanyi, M., Meyerson, M., Singer, S., & Sander, C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003179 · Cited by 170 · cited 2×
“For example, Taylor and colleagues proved that there was no CDK4 gene amplification in UHGPS (18).”
DNA fingerprinting of the NCI-60 cell line panel
Lorenzi, P. L., Reinhold, W. C., Varma, S., Hutchinson, A. A., Pommier, Y., Chanock, S. J., & Weinstein, J. N. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0921 · Cited by 166 · cited 1×
“All cells were newly DNA fingerprinted to confirm identity as previously described (25).”
Cited by
Advances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.8 · Cited by 799
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., Cortes, J., Iafrate, A. J., Nuciforo, P., & Tabernero, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt419 · Cited by 365
Chi, Y., Fang, Z., Hong, X., Yao, Y., Sun, P., Wang, G., Du, F., Sun, Y., Wu, Q., Qu, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3766 · Cited by 334
Self-citationDawnRank: discovering personalized driver genes in cancer
Hou, J. P., & Ma, J. (2014) · Genome Medicine · doi:10.1186/preaccept-1835019729127471 · Cited by 273
Ricciotti, R. W., Baraff, A. J., Jour, G., Kyriss, M., Wu, Y., Liu, Y., Li, S.-C., Hoch, B., & Liu, Y. J. (2017) · Cancer Genetics · doi:10.1016/j.cancergen.2017.09.005 · Cited by 67
Metadata
- Authors
- Zhang, K., Chu, K., Wu, X., Gao, H., Wang, J., Yuan, Y.-C., Loera, S., Ho, K., Wang, Y., Chow, W., Un, F., Chu, P., & Yen, Y.
- Venue
- Cancer Research
- Published
- 2013-02-14
- Volume
- 73
- Issue
- 4
- Pages
- 1298-1307
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1994487360
- Cited by
- 98
- References
- 4
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amplification of FRS2 and Activation of FGFR/FRS2 Signaling Pathway in High-Grade Liposarcoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-2086
- The paper
- Zhang, K., Chu, K., Wu, X., Gao, H., Wang, J., Yuan, Y.-C., Loera, S., Ho, K., Wang, Y., Chow, W., Un, F., Chu, P., & Yen, Y. (2013). Amplification of FRS2 and Activation of FGFR/FRS2 Signaling Pathway in High-Grade Liposarcoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-2086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.